DNA sequence specificity of antitumor agents. Oncogenes as possible targets for cancer therapy.
about
Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells.Theoretical studies employing an ab initio and molecular modeling combination method on the DNA binding of bis-benzimidazoles designed for bioreductive activation.AT-rich islands in genomic DNA as a novel target for AT-specific DNA-reactive antitumor drugs.Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.Occurrence of DNA sequences specifically recognized by drugs in human promoters.Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase.
P2860
DNA sequence specificity of antitumor agents. Oncogenes as possible targets for cancer therapy.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
DNA sequence specificity of an ...... le targets for cancer therapy.
@en
DNA sequence specificity of an ...... le targets for cancer therapy.
@nl
type
label
DNA sequence specificity of an ...... le targets for cancer therapy.
@en
DNA sequence specificity of an ...... le targets for cancer therapy.
@nl
prefLabel
DNA sequence specificity of an ...... le targets for cancer therapy.
@en
DNA sequence specificity of an ...... le targets for cancer therapy.
@nl
P2093
P2860
P1433
P1476
DNA sequence specificity of an ...... le targets for cancer therapy.
@en
P2093
P2860
P304
P356
10.3109/02841868809093578
P577
1988-01-01T00:00:00Z